Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1976 Oct;10(4):691–696. doi: 10.1128/aac.10.4.691

Antiviral Activity of BL-3849A, a Low-Molecular-Weight Oral Interferon Inducer1

Earl R Kern *, John R Hamilton †, James C Overall Jr †, Lowell A Glasgow †
PMCID: PMC429816  PMID: 185953

Abstract

Oral administration of BL-3849A to adult mice resulted in peak serum interferon titers of 4,000 units from 15 to 30 h after administration, with detectable levels persisting until 48 h. After intraperitoneal (i.p.) inoculation, peak serum interferon titers of 1,000 to 3,000 units were noted between 9 and 18 h. Multiple injections of the inducer by either route resulted in a marked decrease in the interferon response with each successive dose. In mice infected intranasally with the Rochester mouse virus strain of encephalomyocarditis virus, oral treatment with BL-3849A reduced mortality when initiated either 18 h before or 1 h after infection. In contrast, administration of drug by the i.p. route decreased mortality only if begun before infection. In mice inoculated i.p. with encephalomyocarditis virus, treatment by both the oral and the i.p. route decreased the mortality whether initiated 18 h before or 1 h after infection. Treatment by the oral, but not the i.p., route reduced mortality of mice inoculated i.p. with Semliki forest virus or Herpesvirus hominis type 2. BL-3849A appeared to be as effective as tilorone hydrochloride, but less effective than polyriboinosinic-polyribocytidylic acid, in the treatment of these viral infections of mice.

Full text

PDF
691

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. De Clercq E. Hyporeactivity to interferon production by double-stranded RNA associated with hyporeactivity to antiviral protection and hyporeactivity to toxicity. Proc Soc Exp Biol Med. 1972 Oct;141(1):340–345. doi: 10.3181/00379727-141-36772. [DOI] [PubMed] [Google Scholar]
  2. Gláz E. T., Szolgay E., Stöger I., Tálas M. Antiviral activity and induction of interferon-like substance by quinacrine and acranil. Antimicrob Agents Chemother. 1973 May;3(5):537–541. doi: 10.1128/aac.3.5.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hoffman W. W., Korst J. J., Niblack J. F., Cronin T. H. N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl) propanediamine: antiviral activity and interferon stimulation in mice. Antimicrob Agents Chemother. 1973 Apr;3(4):498–502. doi: 10.1128/aac.3.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kaufman H. E., Centifanto Y. M., Ellison E. D., Brown D. C. Tilorone hydrochloride: human toxicity and interferon stimulation. Proc Soc Exp Biol Med. 1971 May;137(1):357–360. doi: 10.3181/00379727-137-35576. [DOI] [PubMed] [Google Scholar]
  5. Kern E. R., Glasgow L. A., Overall J. C., Jr Antiviral activity of an extract of Brucella abortus: induction of interferon and immunopotentiation of host resistance. Proc Soc Exp Biol Med. 1976 Jul;152(3):372–376. doi: 10.3181/00379727-152-39399. [DOI] [PubMed] [Google Scholar]
  6. Kern E. R., Overall J. C., Jr, Glasgow L. A. Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. J Infect Dis. 1973 Sep;128(3):290–299. doi: 10.1093/infdis/128.3.290. [DOI] [PubMed] [Google Scholar]
  7. Kern E. R., Overall J. C., Jr, Glasgow L. A. Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid. Antimicrob Agents Chemother. 1975 Jun;7(6):793–800. doi: 10.1128/aac.7.6.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kramer M. J., Cleeland R., Grunberg E. Antiviral activity of 10-carboxymethyl-9-acridanone. Antimicrob Agents Chemother. 1976 Feb;9(2):233–238. doi: 10.1128/aac.9.2.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Krueger R. E., Mayer G. D. Tilorone hydrochloride: an orally active antiviral agent. Science. 1970 Sep 18;169(3951):1213–1214. doi: 10.1126/science.169.3951.1213. [DOI] [PubMed] [Google Scholar]
  10. Murphy B. R., Glasgow L. A. Factors modifying host resistance to viral infection. 3. Effect of whole body x-irradiation on experimental encephalomyocarditis virus infection in mice. J Exp Med. 1968 May 1;127(5):1035–1052. doi: 10.1084/jem.127.5.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nichol F. R., Weed S. D., Underwood G. E. Stimulation of murine interferon by a substituted pyrimidine. Antimicrob Agents Chemother. 1976 Mar;9(3):433–439. doi: 10.1128/aac.9.3.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Olsen G. A., Kern E. R., Glasgow L. A., Overall J. C. Effect of treatment with exogenous interferon, polyinosinic acid-polyctyidylic acid or polyinosinic acid-polycytidylic acid-poly-L-lysine complex on encephalomyocarditis virus infections in mice. Antimicrob Agents Chemother. 1976 Oct;10(4):668–676. doi: 10.1128/aac.10.4.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Saito N., Suzuki F., Sasaki K., Ishida N. Antiviral and interferon-inducing activity of a new glutarimide antibiotic, 9-methylstreptimidone. Antimicrob Agents Chemother. 1976 Jul;10(1):14–19. doi: 10.1128/aac.10.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sharpe T. J., Birch P. J., Planterose D. N. Resistance to virus infection during the hyporeactive state of interferon induction. J Gen Virol. 1971 Sep;12(3):331–333. doi: 10.1099/0022-1317-12-3-331. [DOI] [PubMed] [Google Scholar]
  15. Siminoff P., Bernard A. M., Hursky V. S., Price K. E. BL-20803, a new, low-molecular-weight interferon inducer. Antimicrob Agents Chemother. 1973 Jun;3(6):742–743. doi: 10.1128/aac.3.6.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Soehner R. L., Gambardella M. M., Hou E. F., Pollard M. Oral induction of interferon by a low-molecular-weight compound. Proc Soc Exp Biol Med. 1974 Mar;145(3):1114–1119. doi: 10.3181/00379727-145-37963. [DOI] [PubMed] [Google Scholar]
  17. Stringfellow D. A., Glasgow L. A. Hyporeactivity of infection: potential limitation to therapeutic use of interferon-inducing agents. Infect Immun. 1972 Nov;6(5):743–747. doi: 10.1128/iai.6.5.743-747.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Stringfellow D. A., Glasgow L. A. Tilorone hydrochloride: an oral interferon-inducing agent. Antimicrob Agents Chemother. 1972 Aug;2(2):73–78. doi: 10.1128/aac.2.2.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stringfellow D. A., Overall J. C., Jr, Glasgow L. A. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis. J Infect Dis. 1974 Nov;130(5):470–480. doi: 10.1093/infdis/130.5.470. [DOI] [PubMed] [Google Scholar]
  20. Stringfellow D. A., Overall J. C., Jr, Glasgow L. A. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. II. Effect of multiple doses of polyriboinosinic-polyribocytidylic acid on viral pathogenesis. J Infect Dis. 1974 Nov;130(5):481–488. doi: 10.1093/infdis/130.5.481. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES